Allient (ALNT) Competitors $44.00 -2.17 (-4.70%) Closing price 04:00 PM EasternExtended Trading$44.00 -0.01 (-0.01%) As of 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALNT vs. TXG, TRNS, EYPT, AEHR, CTKB, LAB, SENS, FEIM, QSI, and MASSShould you be buying Allient stock or one of its competitors? The main competitors of Allient include 10x Genomics (TXG), Transcat (TRNS), Eyepoint Pharmaceuticals (EYPT), Aehr Test Systems (AEHR), Cytek Biosciences (CTKB), Standard BioTools (LAB), Senseonics (SENS), Frequency Electronics (FEIM), Quantum-Si (QSI), and 908 Devices (MASS). These companies are all part of the "measuring and control equipment" industry. Allient vs. Its Competitors 10x Genomics Transcat Eyepoint Pharmaceuticals Aehr Test Systems Cytek Biosciences Standard BioTools Senseonics Frequency Electronics Quantum-Si 908 Devices Allient (NASDAQ:ALNT) and 10x Genomics (NASDAQ:TXG) are both small-cap measuring and control equipment companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, profitability, valuation, risk, institutional ownership and dividends. Do institutionals and insiders hold more shares of ALNT or TXG? 61.6% of Allient shares are owned by institutional investors. Comparatively, 84.7% of 10x Genomics shares are owned by institutional investors. 15.6% of Allient shares are owned by company insiders. Comparatively, 9.4% of 10x Genomics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has more risk and volatility, ALNT or TXG? Allient has a beta of 1.52, meaning that its share price is 52% more volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 2.03, meaning that its share price is 103% more volatile than the S&P 500. Is ALNT or TXG more profitable? Allient has a net margin of 2.75% compared to 10x Genomics' net margin of -13.13%. Allient's return on equity of 9.97% beat 10x Genomics' return on equity.Company Net Margins Return on Equity Return on Assets Allient2.75% 9.97% 4.67% 10x Genomics -13.13%-12.88%-10.03% Does the media refer more to ALNT or TXG? In the previous week, 10x Genomics had 22 more articles in the media than Allient. MarketBeat recorded 29 mentions for 10x Genomics and 7 mentions for Allient. Allient's average media sentiment score of 0.82 beat 10x Genomics' score of 0.55 indicating that Allient is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allient 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 10x Genomics 6 Very Positive mention(s) 6 Positive mention(s) 10 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer ALNT or TXG? Allient currently has a consensus price target of $35.00, suggesting a potential downside of 20.45%. 10x Genomics has a consensus price target of $13.54, suggesting a potential upside of 2.28%. Given 10x Genomics' stronger consensus rating and higher possible upside, analysts clearly believe 10x Genomics is more favorable than Allient.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Allient 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.0010x Genomics 1 Sell rating(s) 6 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.38 Which has stronger earnings and valuation, ALNT or TXG? Allient has higher earnings, but lower revenue than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Allient, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAllient$529.97M1.41$13.17M$0.8651.1610x Genomics$610.78M2.67-$182.63M-$0.70-18.91 SummaryAllient and 10x Genomics tied by winning 8 of the 16 factors compared between the two stocks. Get Allient News Delivered to You Automatically Sign up to receive the latest news and ratings for ALNT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALNT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALNT vs. The Competition Export to ExcelMetricAllientELEC IndustryComputer SectorNASDAQ ExchangeMarket Cap$782.44M$5.81B$30.05B$9.84BDividend Yield0.26%2.74%3.08%4.07%P/E Ratio51.1623.0452.1925.74Price / Sales1.412.371,274.26115.83Price / Cash15.2223.6336.4959.48Price / Book2.582.269.126.15Net Income$13.17M$171.66M$803.97M$265.06M7 Day Performance4.07%2.48%1.26%2.80%1 Month Performance12.50%4.96%0.76%1.68%1 Year Performance111.54%11.58%24,023.69%29.59% Allient Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALNTAllient2.9097 of 5 stars$44.00-4.7%$35.00-20.5%+119.9%$782.44M$529.97M51.162,525TXG10x Genomics3.7415 of 5 stars$12.31+0.2%$13.63+10.7%-37.0%$1.51B$610.78M-17.591,240Trending NewsEarnings ReportAnalyst ForecastTRNSTranscat3.5289 of 5 stars$79.38+0.3%$112.20+41.3%-27.1%$737.89M$278.42M55.511,245News CoveragePositive NewsAnalyst RevisionEYPTEyepoint Pharmaceuticals1.8351 of 5 stars$10.27+0.4%$25.78+151.0%+40.3%$703.94M$43.27M-3.83120AEHRAehr Test Systems2.2553 of 5 stars$17.48-4.0%N/A+46.5%$544.45M$58.97M-134.4590Gap DownCTKBCytek Biosciences3.2795 of 5 stars$3.79-6.0%$5.60+47.8%-22.1%$512.71M$200.45M-75.80500Gap DownLABStandard BioTools3.0069 of 5 stars$1.28-2.3%$2.50+96.1%-19.6%$495.67M$174.43M-3.64620Analyst DowngradeGap DownSENSSenseonics2.3003 of 5 stars$0.47-5.9%$1.55+232.3%+22.4%$305.13M$25.47M-3.5990Analyst RevisionFEIMFrequency Electronics1.5088 of 5 stars$29.17-1.2%N/A+159.8%$287.27M$69.81M11.81200News CoverageQSIQuantum-Si3.0484 of 5 stars$1.20-5.5%$3.48+189.6%+28.6%$233.04M$3.06M-1.76150MASS908 Devices3.1041 of 5 stars$6.43+1.6%$8.00+24.4%+65.9%$227M$59.63M-11.9160 Related Companies and Tools Related Companies 10x Genomics Alternatives Transcat Alternatives Eyepoint Pharmaceuticals Alternatives Aehr Test Systems Alternatives Cytek Biosciences Alternatives Standard BioTools Alternatives Senseonics Alternatives Frequency Electronics Alternatives Quantum-Si Alternatives 908 Devices Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALNT) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredOne stock to replace NvidiaInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allient Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allient With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access